Replies to post #47872 on Ariad Pharmaceuticals Inc fka ARIA

[gdollasign]

Still, I were ARIA's general counsel, I would tell Berger to STFU....

So here are a few (not all) of HB's favorited tweets (none of them in their entirety)...some odd stuff so enjoy them for what they are worth...absolutely nada except that no CEO in their right mind would acknowledge some of these.



*AMGN: MM- Kyprolis- CV event concern (believe this is where Tom Silver got his MM thoughts for the next drug)
*GILD: Article on Sovaldi pricing
*BMY, MRK, NVS, AZN: Leerink Immuno-Oncology
*RXDX: Seeking Alpha ALK space, ARIAD (AP26113) mention as competition (HB only favorite)
*PRAN: Going to zero on AD drug failure
*ARIA: Is ARIA a threat or opportunity vs NVS....LLY and GSK mention
*ARIA: A lot of hiring in January...looking for 9 Dir and Mgrs....
*ARIA: On long list of marijuana stocks (although Ariad not mentioned on blogspot cited) (HB only favorite)
*Peripheral Neuropathy skin cream (no ARIA mention)
*ARIA: AF worse than pond SCUM. FDA mention allowing Iclusig back on market. (HB only favorite)
*Article Nobel Prize winner: Cell communication
*FiercePharma article: Would ELY or anyone bid for ARIA with Iclusig back on Mkt.
*Accelerated approval pathway (JAMA article) lessons from Iclusig (HB only favorite)
*BMO: GIST 4th line limited potential (HB only favorite)
*Deloitte medical innovation article (no ARIA mention)
*Jorge Cortes interview on Ponatinib and CML
*Chartist info on ARIA above $7 (HB only favorite)
*INCY reports Inducement grant under NASDAQ listing rule. (HB only favorite) phrmwb.com/KYfJfA (hmmmm)
*FDA social media guidance
*New GPCR techniques